A Study to Evaluate Efficacy and Safety of GSK3858279 in Diabetic Peripheral Neuropathic Pain

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Pain

In brief

This is a multicenter randomized, double-blind, placebo-controlled phase 2 study to evaluate efficacy, safety, tolerability, pharmacokinetics, and target engagement of GSK3858279 in adult participants with chronic Diabetic Peripheral Neuropathic Pain (DPNP). The primary objective of the study is to assess the efficacy of GSK3858279 in participants with DPNP who have been unable to sufficiently manage their pain.

Key facts

Study ID

NCT05838755

Run by

GlaxoSmithKline

People needed

147

Starts

2023-09-20

Expected to finish

2025-02-17

Last updated by the study team

2025-11-21

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participant must be 18-75 years of age inclusive, at the time of signing the informed consent.
• Type I or Type II diabetes with painful, distal, symmetrical, sensory motor neuropathy attributed to diabetes, of at least 6 months duration.
• A pain score ≥4 and less than or equal to (≤) 9 by the 11-point NRS (0-10) for average daily pain intensity over the past 24 hours at the screening visit.
• Body mass index (BMI) within the range 18-40 kilogram per meter square (kg/m\^2) (inclusive)
• Capable of giving signed informed consent.

You may not qualify if…

• History or presence of cardiovascular, renal, gastrointestinal, lymphatic disorders which in the opinion of the investigator would interfere with the study procedures and/or assessments.
• Participant has current painful peripheral neuropathy due to a cause other than diabetes (e.g. pernicious anemia, hypothyroidism, post-herpetic neuralgia).
• History of significant allergies to monoclonal antibodies.
• Current enrolment or past participation in a clinical study of an investigational medicinal product intervention within the last 30 days or 5 half-lives (whichever is longer) of signing consent.
• Participants who are unlikely to comply with the protocol (e.g. uncooperative attitude, inability to return for subsequent visits, inability to complete the eDiary daily etc.) and/or otherwise considered by the Investigator to be unlikely to complete the study.

Where it is running

• GSK Investigational Site — Surprise, Arizona, United States
• GSK Investigational Site — Cerritos, California, United States
• GSK Investigational Site — Lomita, California, United States
• GSK Investigational Site — Largo, Florida, United States
• GSK Investigational Site — Miami, Florida, United States
• GSK Investigational Site — Miami, Florida, United States
• GSK Investigational Site — West Palm Beach, Florida, United States
• GSK Investigational Site — Decatur, Georgia, United States
• GSK Investigational Site — Chicago, Illinois, United States
• GSK Investigational Site — Waltham, Massachusetts, United States
• GSK Investigational Site — Williamsville, New York, United States
• GSK Investigational Site — Huntersville, North Carolina, United States
• GSK Investigational Site — Lancaster, South Carolina, United States
• GSK Investigational Site — Cypress, Texas, United States
• GSK Investigational Site — DeSoto, Texas, United States
• GSK Investigational Site — Houston, Texas, United States
• GSK Investigational Site — McAllen, Texas, United States
• GSK Investigational Site — Bellevue, Washington, United States
• GSK Investigational Site — New Westminster, British Columbia, Canada
• GSK Investigational Site — Vancouver, British Columbia, Canada
• GSK Investigational Site — Winnipeg, Manitoba, Canada
• GSK Investigational Site — Toronto, Ontario, Canada
• GSK Investigational Site — Toronto, Ontario, Canada
• GSK Investigational Site — Beijing, China
• GSK Investigational Site — Anniston, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.